Navigation Links
NuVasive to Present at Bank of America and Merrill Lynch 2009 Healthcare Conference
Date:5/7/2009

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer and Kevin O'Boyle, Executive Vice President & Chief Financial Officer, are scheduled to present at the Bank of America and Merrill Lynch 2009 Healthcare Conference at The Palace Hotel in New York, New York on Thursday, May 14, 2009, at 9:20 a.m. ET.

A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentation will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:
    Kevin C. O'Boyle
    EVP & Chief Financial Officer
    NuVasive, Inc.
    858-909-1998
    investorrelations@nuvasive.com

    Investors:
    Patrick F. Williams
    Vice President, Finance & Investor Relations
    NuVasive, Inc.
    858-638-5511
    investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    646-536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive Reports First Quarter 2009 Financial Results
2. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
3. NuVasive Announces Conference Call and Webcast of First Quarter 2009 Results
4. NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference
5. NuVasive to Present at Barclays Capital Global Healthcare Conference
6. NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
7. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
8. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
9. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
10. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
11. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a trusted advisor to the U.S. ... industry white paper, entitled Barriers to Adoption of the ERA and EFT Transactions ...
(Date:9/19/2017)... ... , ... Driving Dynamics Inc., announced today it has been selected as a ... of its mission to continually monitor the training marketplace for the best providers of ... Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular ... ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been ... a trusted, well-respected brand reliant on the healing properties of plants, a proven ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... the Davidson Fellows Scholarship on September 27 at a reception in Washington D.C. ... Engineering, Mathematics, Literature and Music. , “I am honored to be a Davidson ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: